

# Long COVID and the implications for the future of healthcare

Nicola Oliver, Longevity/mortality expert, Medical Intelligence, Cochair COVID-ARG

Josephine Robertson, H & C actuary, COVID-ARG/ICAT volunteer


# **Long COVID**

**Definitions** Clinical picture Prevalence **Predictors Impact** 



# **Long COVID**

#### **Definitions**





### **Organ systems**

#### Endocrine



- New or worsening control of diabetes
- Subacute thyroiditis
- Bone mineral thinning

#### Neuropsychiatric



- Fatigue
- Sleep disturbances
- Myalgia
- Headache
- Brain fog
- PTSD

#### Haematologic




Thromboembolic events



#### Clinical picture - II


#### **Organ systems**

#### Respiratory




- Pulmonary fibrosis
- Reduced pulmonary function

#### Renal



- Acute kidney injury
- Chronic kidney disease

#### Cardiovascular



- Myocarditis
- Myocardial fibrosis



# **COVERSCAN Study**

#### Clinical picture - III




Figure 2 Percentage of patients (black) and controls (grey) with individual organ measures outside of the predefined normal range. Lines represent significant difference in the proportions between the two groups, with \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. LV, left ventricular.



# **COVERSCAN Study**

#### Clinical picture - IV





Figure 4 Percentage of reported symptoms during the acute phases of the illness within those with evidence of organ impairment for each organ separately. Darker red indicates higher percentage of reported symptoms per impaired organ. There are no distinct patterns of symptoms relating to each impaired organ, but a high burden of symptoms in individuals is highlighted.



### **Categories of long COVID**

**Definitions** 






## Office for National Statistics - I (ONS) Prevalence - I

Period post infection	Estimate	Lower 95% confidence interval limit	Upper 95% confidence interval limit
Any duration	1094	1060	1128
Duration at least 12 weeks	697	671	723


Number of people (thousands), four-week period ending 6 March 2021, UK, reporting COVID symptoms



### **ONS** prevalence - II




#### Prevalence - II





#### **Predictors of risk**


Predictors - I






### **COVID Symptom Study I**

Predictors - II




HA = headache

FA = fatigue







#### **Impact**




28 April 2021 13






A model framework for projecting the prevalence and impact of Long-COVID in the UK



Possible pathways of care where long COVID can emerge



#### Estimating prevalence of symptoms



# Symptomatic Long COVID

- Group 2 & 3
- Hospitalised and Non

#### **COVID** injured

- Group 1
- Long tail of permanent injury
- Hospitalised





#### Estimating the QALY impact

**Equation 1** 

$$\Delta Q_{COVID} = \sum_{\substack{Cohort = (symptomatic\ COVID,\\ COVID\ injured)}} \left(\sum_{t=0}^{t=time\ horizon} \frac{T_I * P_{Cohort,t} * (1 - U_{Cohort})}{365.25 * (1 + d)^{\frac{t}{365.25}}}\right)$$


Symptom prevalence across studies identified in the UK by duration and severity groups

#### Where:

- $\Delta Q_{COVID}$  is the number of lost QALYs across the population as a result of COVID infection;
- *t* is the day with respect to time zero;
- $T_I$  is the total number of people infected;
- $P_{Cohort,t}$  is the proportion of all infections that are symptomatic on day t;
- $U_{Cohort}$  is the change in utility based on the quality-of-life index for a person who is symptomatic in each cohort; and
- d is the annual discount rate.



A model framework for projecting the prevalence and impact of Long-COVID in the UK



Cumulative lost QALYs for symptomatic COVID and permanent injury due to COVID



### Long COVID Burden

- Rates of COVID and Long COVID
  - Disproportionately affected communities, occupations
  - Ability to accommodate lasting symptoms
- Cascade of poor outcomes
  - Employment
  - Income
- Direct and indirect affects
  - Health and Care Services
  - Societal and Economic

"to manage these symptoms appropriately and maximise the functional return of COVID-19 survivors" (Halpin et al.)

# **Questions**

# Comments

The views expressed in this [publication/presentation] are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this [publication/presentation] and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this [publication/presentation].

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this [publication/presentation] be reproduced without the written permission of the IFoA [or authors, in the case of non-IFoA research].



28 April 2021 20